Zynlonta
Payments companies reported to CMS as associated with Zynlonta. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Zynlonta, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Zynlonta
These are the largest totals companies reported as associated with Zynlonta. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Rafic Farah | Seattle, WA | Medical Oncology | $66,449.47 |
| Cyrus Khan | Pittsburgh, PA | Hematology & Oncology | $54,254.23 |
| Adolfo Diaz | San Antonio, TX | Hematology & Oncology | $34,834.98 |
| Mark Fesler | Saint Louis, MO | Hematology & Oncology | $28,673.03 |
| Yazan Samhouri | Gilbert, AZ | Hematology & Oncology | $28,290.40 |
| Amitkumar Mehta | Birmingham, AL | Hematology & Oncology | $21,780.66 |
| Michael Bishop | Chicago, IL | Hematology & Oncology | $15,666.18 |
| Syed Ali | Springfield, MA | Medical Oncology | $15,127.94 |
| Izidore Lossos | Miami, FL | Hematology & Oncology | $14,800.00 |
| Abraham Kanate | Morgantown, WV | Hematology & Oncology | $14,727.03 |
Prescribed Zynlonta?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.